Stada Arzneimittel (SAZ) Receives €73.49 Average Price Target from Analysts

Shares of Stada Arzneimittel (ETR:SAZ) have been assigned a consensus rating of “Sell” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is €73.49 ($90.73).

A number of equities research analysts have commented on SAZ shares. Nord/LB set a €74.40 ($91.85) price objective on shares of Stada Arzneimittel and gave the company a “sell” rating in a research report on Wednesday, December 20th. Warburg Research set a €74.40 ($91.85) price objective on shares of Stada Arzneimittel and gave the company a “sell” rating in a research report on Friday, March 9th. Cfra set a €70.00 ($86.42) price objective on shares of Stada Arzneimittel and gave the company a “sell” rating in a research report on Monday, March 12th. Independent Research set a €89.00 ($109.88) price objective on shares of Stada Arzneimittel and gave the company a “neutral” rating in a research report on Monday, March 12th. Finally, Commerzbank set a €66.25 ($81.79) price objective on shares of Stada Arzneimittel and gave the company a “sell” rating in a research report on Tuesday, December 26th.

How to Become a New Pot Stock Millionaire

Shares of SAZ opened at €84.12 ($103.85) on Friday. Stada Arzneimittel has a 12 month low of €53.41 ($65.94) and a 12 month high of €90.24 ($111.41).

COPYRIGHT VIOLATION WARNING: “Stada Arzneimittel (SAZ) Receives €73.49 Average Price Target from Analysts” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/16/stada-arzneimittel-saz-receives-73-49-average-price-target-from-analysts.html.

Stada Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.

Analyst Recommendations for Stada Arzneimittel (ETR:SAZ)

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply